236 related articles for article (PubMed ID: 15668348)
21. Cost-effectiveness of the implantable cardioverter defibrillator?
Hlatky MA; Bigger T
Lancet; 2001 Jun; 357(9271):1817-8. PubMed ID: 11410185
[No Abstract] [Full Text] [Related]
22. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
[TBL] [Abstract][Full Text] [Related]
23. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
24. Regression methods for cost-effectiveness analysis with censored data.
Willan AR; Lin DY; Manca A
Stat Med; 2005 Jan; 24(1):131-45. PubMed ID: 15515137
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators.
Kruger A; Aronow WS; Lai H; Desai H; Singla A; Frishman WH; Cohen M; Sorbera C
Am J Ther; 2009; 16(4):323-5. PubMed ID: 19617719
[TBL] [Abstract][Full Text] [Related]
26. Over-AVID subgroup analysis.
Goldberger JJ; Parker MA; Kadish AH
J Am Coll Cardiol; 2001 Nov; 38(5):1586-7. PubMed ID: 11691549
[No Abstract] [Full Text] [Related]
27. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
Ho AT; Pai SM; Timothy P; Pai RG
Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
[TBL] [Abstract][Full Text] [Related]
28. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
Fogoros RN
Control Clin Trials; 1996 Jun; 17(3 Suppl):37S-46S. PubMed ID: 8877266
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the AVID and DAVID trials of implantable defibrillators.
Sharma A; Epstein AE; Herre JM; Klein RC; Platia EV; Wilkoff B; Ledingham RB; Greene HL; Hallstrom AP;
Am J Cardiol; 2005 Jun; 95(12):1431-5. PubMed ID: 15950565
[TBL] [Abstract][Full Text] [Related]
30. Transvenous implantable cardioverter-defibrillator leads: the weakest link.
Maisel WH
Circulation; 2007 May; 115(19):2461-3. PubMed ID: 17502585
[No Abstract] [Full Text] [Related]
31. Drugs for ventricular arrhythmias in the era of the implantable cardioverter defibrillator.
Peters NS
Eur Heart J; 1999 Mar; 20(5):321-3. PubMed ID: 10206376
[No Abstract] [Full Text] [Related]
32. Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
Curtis AB
J Am Coll Cardiol; 2008 Aug; 52(7):557-8. PubMed ID: 18687250
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
[TBL] [Abstract][Full Text] [Related]
34. Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients.
Bestetti R; Cardinalli-Neto A
Europace; 2009 Apr; 11(4):537. PubMed ID: 19279026
[No Abstract] [Full Text] [Related]
35. Are implantable cardioverter- defibrillators cost-effective?
Naik AM; Peter CT
Curr Cardiol Rep; 2000 Jul; 2(4):341-5. PubMed ID: 10953269
[TBL] [Abstract][Full Text] [Related]
36. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
Exner DV; Klein GJ
J Cardiovasc Electrophysiol; 2003 Jun; 14(6):574-7. PubMed ID: 12875415
[No Abstract] [Full Text] [Related]
37. Sudden death and hypertrophic cardiomyopathy: a review.
Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the implantable cardioverter defibrillator.
Hlatky MA; Sanders GD; Owens DK
Card Electrophysiol Rev; 2003 Dec; 7(4):479-82. PubMed ID: 15071279
[TBL] [Abstract][Full Text] [Related]
39. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
40. Letter by Boriani et al regarding article, "Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study".
Boriani G; Diemberger I; Grigioni F
Circulation; 2008 Sep; 118(14):e515; author reply e516. PubMed ID: 18824650
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
